导航
| 统计阶段 | 收益率 | 同类排名 |
|---|---|---|
| 今年以来 | -3.16% | 3199/4773 |
| 近一周 | -1.29% | 1963/5465 |
| 近一月 | -7.23% | 4508/5421 |
| 近一季 | 10.93% | 195/5231 |
| 近半年 | -1.95% | 1958/4920 |
| 近一年 | -16.00% | 3798/4394 |
| 近两年 | 19.47% | 2661/2954 |
| 近三年 | -10.08% | 2033/2253 |
| 成立以来 | 27.60% | - |
| 年份 | 年收益 | 1季度 | 2季度 | 3季度 | 4季度 |
| 2026 | - - |
-2.05% 2648/4961 |
-5.78% 3620/5312 |
- - |
- - |
| 2025 | 6.40% 2963/4813 |
1.72% 1562/3635 |
2.42% 1579/4076 |
16.87% 2589/4524 |
-12.62% 4264/4813 |
| 2024 | -12.80% 2391/3463 |
-11.00% 2399/2808 |
-8.68% 2267/3014 |
18.33% 1023/3129 |
-9.34% 2921/3463 |
| 2023 | -11.28% 1388/2656 |
1.48% 1564/2280 |
-8.59% 2005/2385 |
-2.24% 645/2515 |
-2.17% 437/2655 |
| 2022 | -20.76% 993/2207 |
-11.95% 559/1919 |
-2.22% 1767/2016 |
-16.29% 1438/2113 |
9.95% 188/2208 |
| 2021 | -5.68% 980/1822 |
-3.74% 823/1255 |
14.72% 246/1330 |
-13.54% 1348/1466 |
-1.21% 1331/1822 |
| 2020 | 52.66% 154/1250 |
8.04% 33/1028 |
30.41% 55/1067 |
3.25% 992/1164 |
4.94% 821/1184 |
| 2019 | 34.72% 392/1092 |
29.51% 269/754 |
-7.30% 551/804 |
6.73% 117/850 |
5.15% 744/918 |
| 2018 | -25.24% 344/834 |
- - |
- - |
- - |
-17.61% 652/691 |
| 2017 | 7.21% 321/714 |
- - |
- - |
- - |
- - |
| 2016 | -13.11% 318/605 |
- - |
- - |
- - |
- - |
| 2015 | 46.95% 27/575 |
- - |
- - |
- - |
- - |
| 2014 | - - |
- - |
- - |
- - |
- - |
| 2013 | - - |
- - |
- - |
- - |
- - |
| 2012 | - - |
- - |
- - |
- - |
- - |
| 基金名称 | 最新净值 | 季增长率 |
| 万家中证港股通创新药ETF | 1.6144 | 32.25% |
| 景顺长城中证港股通创新药ETF | 1.6764 | 32.17% |
| 港股医疗 | 0.9539 | 31.90% |
| 港股医疗ETF | 1.4546 | 31.90% |
| 港股通医疗ETF工银 | 0.9639 | 31.81% |
| 港股通医疗ETF华宝 | 0.9752 | 31.64% |
| 万家中证港股通创新药ETF发起式联接A | 1.4069 | 31.06% |
| 万家中证港股通创新药ETF发起式联接C | 1.4061 | 30.98% |
| 华富中证港股通创新药指数型发起式A | 1.1637 | 30.96% |
| 嘉实中证港股通创新药指数发起式A | 0.8590 | 30.57% |
| 广发中证全指医药卫生ETF VS. 长安沪深300非周期A(740101) |